	US 12,187,781 B2
	Co-receptor affinity enhanced major histocompatibility class II molecules
Marc Kevin Jenkins, Minneapolis, MN (US); Thamotharampillai Dileepan, Minneapolis, MN (US); and Deepali Malhotra, Minneapolis, MN (US)
Assigned to Regents of the University of Minnesota, Minneapolis, MN (US)
Appl. No. 17/264,707
Filed by Regents of the University of Minnesota, Minneapolis, MN (US)
PCT Filed Aug. 1, 2019, PCT No. PCT/US2019/044605 § 371(c)(1), (2) Date Jan. 29, 2021, PCT Pub. No. WO2020/028627, PCT Pub. Date Feb. 6, 2020.
Claims priority of provisional application 62/713,388, filed on Aug. 1, 2018.
Prior Publication US 2021/0300989 A1, Sep. 30, 2021
Int. Cl. G01N 33/50 (2006.01); C07K 14/74 (2006.01); G01N 33/543 (2006.01); G01N 33/58 (2006.01)

CPC C07K 14/70539 (2013.01) [G01N 33/505 (2013.01); G01N 33/54366 (2013.01); G01N 33/582 (2013.01); C07K 2319/00 (2013.01)]

22 Claims

1. A variant major histocompatibility complex class II (MHCII) beta chain comprising an extracellular domain comprising an amino acid substitution in one or more positions, wherein the positions are numbered in correspondence with the amino acid sequence of a wild type MHCII beta chain of SEQ ID NO:9, and wherein the variant comprises the amino acid sequence of SEQ ID NO:8 with an amino acid substitution at position 158 which is L158W or L158D.